Boris C. Pasche
About Boris C. Pasche
Boris C. Pasche serves as the President and CEO of the Barbara Ann Karmanos Cancer Institute and holds a PhD and an M.D. He specializes in gastrointestinal malignancies and hereditary cancer, and has made significant contributions to cancer research and treatment.
Leadership at Barbara Ann Karmanos Cancer Institute
Boris C. Pasche serves as the President and CEO of the Barbara Ann Karmanos Cancer Institute. In this role, he oversees the strategic direction and operational management of the institute, which is dedicated to cancer research, treatment, and education. His leadership is focused on advancing cancer care and improving patient outcomes through innovative research and clinical practices.
Education and Medical Qualifications
Boris C. Pasche holds a Doctor of Philosophy (PhD) and a medical degree (M.D.). His extensive education supports his expertise in oncology and cancer research. He is also a Fellow of the American College of Physicians (FACP), indicating a high level of professional achievement in the field of medicine.
Research Contributions and Innovations
Pasche is the principal investigator of the National Cancer Institute’s Comprehensive Cancer Center Core Grant, which supports significant cancer research initiatives. He co-invented the Therabionic P1 device, showcasing his commitment to developing innovative solutions in cancer treatment. His research includes studying the use of low-level radiofrequency electromagnetic fields for cancer therapy.
Academic Role and Specialization
He holds the position of Chair of the Department of Oncology at Wayne State University School of Medicine. His specialization includes gastrointestinal malignancies and hereditary cancer, where he contributes to both clinical practice and academic research. He is also a scientific member of the Molecular Therapeutics Research Program, focusing on advancing therapeutic approaches in oncology.
Recognition and Awards
Boris C. Pasche was named an Advancements in Care Hero by Crain’s Detroit Business, recognizing his contributions to improving cancer care. This acknowledgment reflects his impact on the field and his commitment to advancing healthcare practices in oncology.